Notably, above mentioned studies evaluating the prognostic potential of PSMA for PCa outcome performed analyses at time of therapy by using RPE specimens, i.e., the assessed PSMA level has no impact on treatment decision. Here, FOLH1 is linked to posterior cortical atrophy.